Interaction entre Buprénorphine et naloxone et Métaxalone
Buprénorphine et naloxone et Métaxalone : les deux notices de prescription signalent cette association dans les termes les plus forts, tels qu'une contre-indication, une mise en garde encadrée ou une consigne de l'éviter.
Ne pas associer sans l'avis d'un prescripteur. Les termes de la notice cités ci-dessous sont les plus forts qu'emploie la FDA.
Ce que disent les notices FDA
D'après la notice Buprénorphine et naloxone (Buprenorphine and Naloxone) · version du 2026-06-16
Examples: phenelzine, tranylcypromine, linezolid Muscle Relaxants Clinical Impact: Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.
Intervention: Monitor patients receiving muscle relaxants and buprenorphine and naloxone sublingual tablets for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of buprenorphine and naloxone sublingual tablets and/or the muscle relaxant as necessary.
Due to the risk of respiratory depression with concomitant use of skeletal muscle relaxants and opioids, strongly consider recommending or prescribing an opioid overdose reversal agent, as is recommended for all patients on buprenorphine and naloxone treatment for opioid use disorder [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3)…
Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.
Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with buprenorphine and naloxone sublingual tablets [see Warnings and Precautions (5.3) , Drug Interactions (7) ] .
D'après la notice Métaxalone (Metaxalone) · version du 2026-02-03
If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases.
If concomitant use of metaxalone and another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases.
Depressants If concomitant use of Metaxalone Tablets, 640 mg and another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage modification.
Due to the additive pharmacologic effect, concomitant use of Metaxalone Tablets, 640 mg with other CNS depressants may increase the risk of sedation and respiratory depression [see Warnings and Precautions (5.2) ].
Central Nervous System (CNS) Depression : Metaxalone Tablets, 640 mg may impair mental and/or physical abilities required for the performance of hazardous tasks, such as operating machinery or driving a motor vehicle, and may enhance the effects of other CNS depressants including alcohol.
Vous prenez autre chose que ces deux-là ? Les interactions se cumulent. Vérifiez toute votre liste en une fois ; elle reste dans votre navigateur.
Ouvrir dans le vérificateurCeci n'est pas un avis médical. Interaction Checker cite le texte des notices FDA et des fiches d'information du NIH. L'importance d'une interaction dans votre cas dépend des doses, des horaires de prise, de la fonction rénale et hépatique et d'autres problèmes de santé. Vérifiez auprès d'un pharmacien ou d'un prescripteur.